Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Ltd ADR (TAK)

Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,617,356
  • Shares Outstanding, K 3,164,818
  • Annual Sales, $ 29,803 M
  • Annual Income, $ 2,346 M
  • 60-Month Beta 0.53
  • Price/Sales 1.54
  • Price/Cash Flow 3.67
  • Price/Book 0.91
Trade TAK with:

Options Overview Details

View History
  • Implied Volatility 27.59% ( +1.71%)
  • Historical Volatility 15.70%
  • IV Percentile 69%
  • IV Rank 35.19%
  • IV High 59.20% on 03/28/24
  • IV Low 10.42% on 05/16/23
  • Put/Call Vol Ratio 0.03
  • Today's Volume 63
  • Volume Avg (30-Day) 181
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 5,713
  • Open Int (30-Day) 4,590

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.39
  • Growth Rate Est. (year over year) +256,053.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.11 +0.38%
on 04/17/24
14.55 -9.55%
on 03/20/24
-1.40 (-9.62%)
since 03/18/24
3-Month
13.11 +0.38%
on 04/17/24
14.88 -11.56%
on 02/27/24
-1.71 (-11.50%)
since 01/18/24
52-Week
13.11 +0.38%
on 04/17/24
17.11 -23.11%
on 05/09/23
-3.55 (-21.24%)
since 04/18/23

Most Recent Stories

More News
One Ultra-Cheap High-Yield Dividend Stock to Buy

Now may be a good time for dividend investors to consider loading up on this stock.

TAK : 13.16 (+0.08%)
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time

There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock...

SNY : 45.39 (-1.56%)
TAK : 13.16 (+0.08%)
NRX.VN : 0.600 (unch)
BMY : 48.30 (+0.96%)
NRX : 0.14 (+7.69%)
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. Positive Opinion...

TAK : 13.16 (+0.08%)
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris

One of these high-yield pharma stocks stands out as a better buy right now.

PFE : 25.39 (-0.12%)
TAK : 13.16 (+0.08%)
VTRS : 11.12 (+0.18%)
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now

These two high-yield dividend stocks are attractive buys right now.

TAK : 13.16 (+0.08%)
T : 16.33 (+1.30%)
Why Shares of Innate Pharma Jumped Thursday

The company's collaboration agreement with Sanofi could soon pay off.

SNY : 45.39 (-1.56%)
TAK : 13.16 (+0.08%)
IPHA : 2.35 (-2.49%)
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational...

TAK : 13.16 (+0.08%)
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday

The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.

AMGN : 262.75 (-0.50%)
GSK : 39.27 (-0.83%)
TAK : 13.16 (+0.08%)
ARWR : 22.61 (+0.36%)
This Supercharged Dividend King Stock Might Soon Run Out of Steam

Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.

JNJ : 145.74 (+0.67%)
PFE : 25.39 (-0.12%)
BMY : 48.30 (+0.96%)
TAK : 13.16 (+0.08%)
GILD : 66.16 (-1.15%)
VRTX : 393.48 (+0.10%)
ABBV : 164.66 (+0.25%)
ABT : 105.27 (-0.59%)
MRK : 125.23 (-0.11%)
RXDX : 199.92 (+0.09%)
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children

Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary...

TAK : 13.16 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 13.32
2nd Resistance Point 13.27
1st Resistance Point 13.22
Last Price 13.16
1st Support Level 13.11
2nd Support Level 13.06
3rd Support Level 13.01

See More

52-Week High 17.11
Fibonacci 61.8% 15.59
Fibonacci 50% 15.11
Fibonacci 38.2% 14.64
Last Price 13.16
52-Week Low 13.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar